Rare Opportunity In The Columbia Seligman Premium Technology Growth CEF
https://seekingalpha.com/article/4681962-rare-opportunity-in-the-columbia-seligman-premium-technology-growth-cef-stk?source=feed_tag_etf_portfolio_strategy
Apr 03, 2024 - STK has historically been the premier option-write technology fund among CEFs, typically trading at a double-digit premium. Read why I'm bullish on the fund.
0
Rare Stock Picks In March 2024 - From 24 Discerning Analysts
https://seekingalpha.com/article/4681746-rare-stock-picks-in-march-2024-from-24-discerning-analysts?source=feed
Apr 03, 2024 - In our monthly Rare Stock Picks series, we're highlighting March 2024 investment picks. Click here for the list of March 2024 Buy recommendations.
0
MP Materials (MP) Receives $58.5M for Rare Earth Magnet Facility
https://www.zacks.com/stock/news/2249320/mp-materials-mp-receives-58-5m-for-rare-earth-magnet-facility?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2249320
Apr 02, 2024 - MP Materials (MP) expects to start the commercial production of finished magnets in late 2025 in its U.S. facility.
0
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
https://www.zacks.com/stock/news/2249187/solid-biosciences-sldb-falls-despite-fda-rare-tag-for-dmd-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249187
Apr 02, 2024 - Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
0
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
https://www.zacks.com/stock/news/2249013/astrazeneca-s-azn-rare-blood-disorder-drug-gets-fda-nod?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249013
Apr 02, 2024 - FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.
0
Rare Buying Opportunity: Big Dividends With Very Attractive Risk-Reward
https://seekingalpha.com/article/4681013-rare-buying-opportunity-big-dividends-attractive-risk-reward?source=feed
Mar 29, 2024 - Check here to learn why now is the perfect time for investors to explore discounted dividend stocks with great potential for high returns and limited risks.
0
NCAA Tournament: Clemson tops Arizona for rare Elite Eight berth
https://www.ocregister.com/2024/03/28/ncaa-tournament-clemson-tops-arizona-for-rare-elite-eight-berth/
Mar 28, 2024 - Chase Hunter scores 18 points and converts a three-point play with 25.7 seconds left, as the sixth-seeded Tigers reach the Elite Eight for the first time since 1980, beating No. 2 seed Arizona, 77-72, in a West Region semifinal at Crypto.com Arena.
0
Applied Therapeutics gets extension of FDA review for rare disease drug
https://seekingalpha.com/news/4085204-applied-therapeutics-gets-extension-fda-review-rare-disease-drug?source=feed_sector_healthcare
Mar 28, 2024 - The U.S. FDA has delayed the review of Applied Therapeutics' NDA for rare drug disease candidate govorestat, causing a 13% drop in after-hours trading. Read more here.
0
InPlay Oil: A Rare 7.6% Yield That Is Also Undervalued
https://seekingalpha.com/article/4680611-inplay-oil-rare-7-6-percent-yield-also-undervalued-ipoof-stock?source=feed_all_articles
Mar 26, 2024 - InPlay Oil is an undervalued Canadian oil and gas producer offering a well-covered 7.6% monthly dividend and potential for high total returns. Read more here.
0
Merck wins FDA approval of sotatercept for rare lung disease
https://seekingalpha.com/news/4084059-merck-wins-fda-approval-sotatercept-rare-lung-disease?source=feed_sector_healthcare
Mar 26, 2024 - Merck sotatercept, approved by the FDA for pulmonary arterial hypertension, offers hope for patients with pulmomary arterial hypertension. Read more here.
0